drugset / Trial / NCT05955313

Effectiveness of Low-dose Naltrexone in Patients With Different Types of Vulvodynia

NCT05955313

Phase 2 Recruiting 300 enrolled Medical University of Lublin
RandomizedParallel-groupSingle-blindTreatment

Summary

Vulvodynia (Vd) is chronic functional vulvar pain, with prevalence of 3-16% and unclear etiopathology. Although Vd significantly deteriorates quality of life, the problem is marginalized, no pharmacologic treatment standards exist. Naltrexone hydrochloride is a specific opioid antagonist with slight agonist activity. There is growing body of evidence supporting the effectiveness of low-dose naltrexone (LDN) in different types of chronic pain. The main goal of this trial is to test the effect of LDN on pain perception and quality of life in women with different types of Vd. Half of the study population receives LDN and the remaining patients take placebo, according to randomization list. This RTC is quadruplet blinded.

Timeline

Start
2023-05-31
Primary completion
2025-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Naltrexone Small molecule 4.5 mg Oral

Indications